Literature DB >> 11701729

Altered neuroregulation of GH secretion in viscerally obese premenopausal women.

H Pijl1, J G Langendonk, J Burggraaf, M Frölich, A F Cohen, J D Veldhuis, A E Meinders.   

Abstract

We used deconvolution analysis of 24-h plasma GH concentration profiles (10- min sampling intervals) to appraise GH secretion rates and elimination kinetics in obese (body mass index, approximately 34 kg/m2) premenopausal women with large visceral fat area (LVFA; n = 8) vs. small visceral fat area (SVFA; n = 8) as determined by magnetic resonance imaging. The subjects were matched for body mass index, body fat percentage, and age. The impact of the loss of 50% of prestudy weight excess induced by caloric restriction was assessed as well. The results were compared with those obtained in normal weight control women (n = 8). LVFA subjects manifested markedly (4-fold) reduced mean plasma GH levels, which was brought about by jointly diminished basal and pulsatile GH secretion. Moreover, visceral obesity was associated with loss of regularity of GH release, as established by the approximate entropy statistic. In contrast, SVFA subjects produced normal daily amounts of GH and exhibited mean 24-h plasma GH concentrations that were similar to those in normal weight controls. GH half-life and distribution volume were not different among the study groups. Importantly, weight loss did not affect the daily GH secretion rate in LVFA women, so that their mean plasma GH concentration remained considerably reduced (approximately 50%) compared with controls (despite the loss of approximately 40% of visceral fat). Normal GH kinetics in SVFA women were not significantly influenced by weight reduction. Thus, GH neuroregulation appears to be particularly altered in obese women with a tendency to store fat in their visceral adipose depot. Because weight loss did not reverse GH secretion rate in viscerally obese women, we speculate that relative hyposomatotropism is a primary feature of these women, which could be involved in their tendency to preferentially store excess fat in visceral adipose tissue.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11701729     DOI: 10.1210/jcem.86.11.8061

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  53 in total

1.  Gender, age, body mass index, and IGF-I individually and jointly determine distinct GH dynamics: analyses in one hundred healthy adults.

Authors:  Johannes D Veldhuis; Ferdinand Roelfsema; Daniel M Keenan; Steven Pincus
Journal:  J Clin Endocrinol Metab       Date:  2010-10-06       Impact factor: 5.958

2.  Determinants of IGF1 and GH across the weight spectrum: from anorexia nervosa to obesity.

Authors:  D J Brick; A V Gerweck; E Meenaghan; E A Lawson; M Misra; P Fazeli; W Johnson; A Klibanski; K K Miller
Journal:  Eur J Endocrinol       Date:  2010-05-25       Impact factor: 6.664

Review 3.  Body composition and skeletal health: too heavy? Too thin?

Authors:  Alexander Faje; Anne Klibanski
Journal:  Curr Osteoporos Rep       Date:  2012-09       Impact factor: 5.096

4.  Effects of GH in women with abdominal adiposity: a 6-month randomized, double-blind, placebo-controlled trial.

Authors:  Miriam A Bredella; Eleanor Lin; Danielle J Brick; Anu V Gerweck; Lindsey M Harrington; Martin Torriani; Bijoy J Thomas; David A Schoenfeld; Anne Breggia; Clifford J Rosen; Linda C Hemphill; Zida Wu; Nader Rifai; Andrea L Utz; Karen K Miller
Journal:  Eur J Endocrinol       Date:  2012-01-24       Impact factor: 6.664

5.  Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.

Authors:  Hideo Makimura; Meghan N Feldpausch; Alison M Rope; Linda C Hemphill; Martin Torriani; Hang Lee; Steven K Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2012-09-26       Impact factor: 5.958

Review 6.  Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS.

Authors:  Shobhit Jain; Ninad Desai; Amrit Bhangoo
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

7.  The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Authors:  Hideo Makimura; Caitlin A Murphy; Meghan N Feldpausch; Steven K Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2013-12-20       Impact factor: 5.958

Review 8.  What Can We Learn from Interventions That Change Fat Distribution?

Authors:  Pornpoj Pramyothin; Kalypso Karastergiou
Journal:  Curr Obes Rep       Date:  2016-06

9.  GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome.

Authors:  F Orio; S Palomba; A Colao; T Russo; C Dentico; L Tauchmanovà; S Savastano; C Nappi; C Sultan; F Zullo; G Lombardi
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

Review 10.  Nanomedicines in the treatment of acromegaly: focus on pegvisomant.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes Romijn
Journal:  Int J Nanomedicine       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.